Mitral Valve Replacement & Endocarditis Risk
Mitral Valve Surgery Substantially Increases Infective Endocarditis Risk, Study Finds
Table of Contents
New research highlights a significant rise in infective endocarditis (IE) following mitral valve replacement, prompting calls for refined preventive strategies.
A decade-long study analyzing Danish registries has revealed a significantly higher risk of infective endocarditis (IE) in patients who have undergone mitral valve replacement (MVR) compared to those who have had mitral valve repair (mvrp) or individuals at moderate risk for the disease. The findings, published in the European Heart Journal, underscore the need for enhanced surveillance and possibly differentiated antibiotic prophylaxis protocols for patients with prosthetic mitral valves.
Key findings: A Stark Contrast in IE Rates
The comprehensive analysis, led by Amna Alhakak, MD, of Copenhagen University Hospital rigshospitalet, compared three groups: patients who underwent mitral valve replacement, those who underwent mitral valve repair, and a control group of individuals at moderate risk for IE.
Over a 10-year period, the study observed the following incidence rates of infective endocarditis:
Mitral Valve Replacement (MVR): 6.1%
Mitral Valve Repair (MVRp): 1.6%
Moderate Risk control Group: 1.7%
Crucially,undergoing MVR was associated with a 3.52-fold higher 10-year rate of IE when compared to individuals at moderate risk (adjusted hazard ratio, 95% CI, 2.73-4.52). In contrast,mitral valve repair did not show a similar elevated risk.
Comparative Risk Analysis
When compared to control individuals, the 10-year rate of IE was dramatically higher across all intervention groups:
MVR: Approximately 66-fold higher
MVRp: Approximately 14-fold higher
Moderate Risk Control Group: Approximately 10-fold higher
Despite these stark differences in IE incidence, the study found that antibiotic prescription redemption after discharge and before IE occurrence was similar across all three groups, ranging from 68% to 77%, with no important variations noted.
Implications for Clinical Practise and Future Research
The study’s findings have significant implications for how clinicians approach IE prevention in patients with mitral valve disease. The substantial increase in IE risk following MVR, in particular, suggests that current preventive strategies may not be sufficiently robust for this patient population.
“Future studies may clarify whether antibiotic prophylaxis should be utilized equally for both [mitral valve] replacement and repair,” the researchers reported. This statement points to a potential need for tailored prophylaxis regimens based on the type of mitral valve intervention.
Daniele Giacoppo, MD, of the University of Catania, Italy, emphasized the value of this research in an accompanying editorial. he stated, “The analysis of Danish registries represents an outstanding opportunity to define the contemporary risk of [infective endocarditis] after MV [mitral valve] repair and MV replacement, providing insights for implementing preventive strategies and surveillance programs for patients who have undergone prosthetic MV replacement and promoting new investigations on preventive treatment requirements between patients who have undergone MV repair and those who have undergone MV replacement.”
This sentiment highlights the study’s contribution to understanding contemporary IE risks and its role in guiding the development of more effective preventive measures and surveillance programs.
Study Limitations and Disclosures
It is significant to acknowledge the limitations of this observational study. While it identified strong associations, it did not definitively prove that mitral valve interventions caused infective endocarditis. The use of the moderate-risk group as a comparator means that the risk for confounding factors remains. Furthermore, microbiological data was not available for the entire follow-up period, which could impact the granularity of the findings.
The research was supported by a grant from the Research Fund of Rigshospitalet, Copenhagen University Hospital. Several authors disclosed receiving honoraria, travel grants, research grants, and lecture fees from various pharmaceutical and healthcare companies, including AstraZeneca, Bayer, and Novo Nordisk Foundation.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.